Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2025—Eppendorf has launched the Eppendorf Research 3 Neo mechanical pipette. Users can choose between two volume settings and speeds. The pipette can be adjusted for different liquid types, tip geometries, and reverse pipetting and a volume lock feature prevents unintentional volume changes. The use of ColorTag marking rings provides color-coded identification.
October 2025—The Food and Drug Administration has granted breakthrough device designation for Quest Diagnostic’s Haystack MRD circulating tumor DNA test. The test is used for identifying minimal residual disease in patients with stage two colorectal cancer following curative-intent surgical treatment who may benefit from adjuvant therapy in accordance with therapeutic product labeling.
October 2025—The FDA has cleared Hardy Diagnostics’ NG-Test CTX-M Multi, an in vitro diagnostic immunoassay for the qualitative detection of CTX-M enzymes (groups 1, 2, 8, 9, and 25) from pure colonies of Enterobacterales suspected of extended-spectrum beta-lactamase production. These enzymes confer resistance to many beta-lactam antibiotics, making infections more difficult to treat. The test delivers results in 15 minutes.
October 2025—Magnified Learning offers consulting services across the spectrum of health care operations, including supply chain management, revenue cycle optimization, operational excellence, and organizational change management. The company’s approach leverages next-generation Lean Six Sigma, clinical integration strategies, and advanced technology platforms to create a sustainable alignment between operational performance and financial outcomes. Magnified Learning also offers online certification programs that feature sophisticated online learning management systems with self-paced curricula, comprehensive content previews, and embedded assessment tools compatible across all major operating systems. Each certification includes continuous learning pathways and recertification opportunities.
September 2025—The FDA has approved Thermo Fisher Scientific’s Oncomine Dx Express test, an in vitro diagnostic assay, for use as a companion diagnostic for Dizal’s Zegfrovy (sunvozertinib) to identify patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations. In addition, the test has been approved for tumor profiling in solid tumors and detects cancer mutations with evidence of clinical significance and potential clinical significance across 46 genes.
September 2025—Proscia partnered with the Dark Intelligence Group to survey more than 360 senior professionals representing independent, hospital, and academic laboratories and published a report on the findings. The “2025 Laboratory Leadership Report: Insights on Digital Pathology, AI, and Precision Medicine” finds that 38 percent of laboratory leaders cite staffing shortages as their biggest challenge and 31 percent cite declining reimbursement as their top concern. The top-ranked opportunities for labs are automation to drive efficiency (30 percent), molecular and genetic testing (29 percent), and artificial intelligence (25 percent).
September 2025—Qiagen is expanding its oncology diagnostics portfolio with two strategic partnerships to advance the use of minimal residual disease testing in clinical trials to support pharma co-development projects for companion diagnostics. Tracer Biotechnologies, a developer of blood-based molecular diagnostics for cancer, is working with Qiagen to create companion diagnostics for MRD testing in solid tumors. The assays, for use on the QIAcuity digital PCR platform, are designed to enable the use of minimally invasive blood samples to monitor residual disease with high sensitivity.
September 2025—Quest Diagnostics has launched a diagnostic laboratory test for the Oropouche virus, an emerging virus in the Americas that is spread to people by infected biting midges and some species of mosquitoes. The viral disease presents clinically with symptoms that overlap with those of other arboviral diseases such as Dengue, Zika, and chikungunya. Quest’s laboratory in San Juan Capistrano, Calif., will perform the test using PCR technology, with serology testing to follow later this quarter.
September 2025—C2N Diagnostics has launched two plasma assays for research use only. C2N eMTBR-tau243 (endogenous microtubule binding region) is a blood test that selectively detects a specific region of tau; this fragment has been shown to closely track insoluble tau aggregates within neurofibrillary tangles in Alzheimer’s disease. The assay builds on the existing C2N eMTBR-tau243 test in cerebrospinal fluid launched by the company nearly two years ago. C2N obtained exclusive rights for these technologies from the Bateman Lab at WashU Medicine, St. Louis, Mo. The company plans to integrate the new plasma C2N eMTBR-tau243 assay into clinical routine in the future.
September 2025—Bruker’s MALDI Biotyper Sirius and Sirius One systems have been awarded the My Green Lab ACT Ecolabel. The MALDI Biotyper systems for microbial identification received an Environmental Impact Factor score of 26.8 (EU and U.K.) and 35.4 (United States).
